Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

The company announced a series B-2 financing of $158m that it plans to use for pivotal Phase II development of TORL-1-23, which it called a first-in-class agent.

Roivant’s brepocitinib bests data Humira previously posted in non-infectious uveitis, a top cause of blindness. The TYK2/JAK1 inhibitor also is in Phase III for dermatomyositis.

After reducing 500 employees last year while reorganizing its subsidiaries in the US in the aftermath of patent expiration for its mainstay product Latuda, the Japanese firm has decided to move ahead with another rationalization affecting 400 employees there.